The approach exploits a blood biopsy to detect circulating tumour DNA (ctDNA), which can be a simple way to test for MRD, based on assessment of BRAF, NRAS, or TERT mutations that are present in more than 75% of melanoma patients’ tumours. The gene discussed is BRAF; the disease is neoplasm.